Literature DB >> 15647717

Advances in diabetes for the millennium: toward a cure for diabetes.

Aaron I Vinik1, David Taylor Fishwick, Gary Pittenger.   

Abstract

What does the future hold for the person with diabetes, since current therapies, including insulin, are all symptomatic and do not address the underlying biology? This article reviews the current state-of-the-art strategies aimed at curing diabetes. The central rationale to curing diabetes revolves around replacing the function of pancreatic islets, either directly through pancreatic/islet transplantation, indirectly through artificial pancreas/beta cells, or via a rebirth of islet function by reprogramming the body to create a new and expanded islet cell mass protected from further assault by autoimmune and other processes. All of these approaches are considered in context of their current status, progress, future challenges or limitations, and long-term prospects for a cure. Although the horizon is in the distance, the advances reviewed in this study predict the future to be bright, and whereas the prospect of islet neogenesis was once considered to be heretical, it is now quite fashionable amongst the scientific community.

Entities:  

Mesh:

Year:  2004        PMID: 15647717      PMCID: PMC1474820     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  19 in total

1.  beta-cell turnover: its assessment and implications.

Authors:  S Bonner-Weir
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

2.  Neogenesis of islet cells.

Authors:  T J Wilkin
Journal:  Diabetes Metab Rev       Date:  1998-12

3.  Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue.

Authors:  H C Lee; S J Kim; K S Kim; H C Shin; J W Yoon
Journal:  Nature       Date:  2000-11-23       Impact factor: 49.962

Review 4.  The use of mycophenolate mofetil in transplant recipients.

Authors:  T S Mele; P F Halloran
Journal:  Immunopharmacology       Date:  2000-05

5.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  The use of intravenous tacrolimus and mycophenolate mofetil as induction and maintenance immunosuppression in simultaneous pancreas--kidney recipients with previous transplants.

Authors:  G Ciancio; J Miller; G W Burke
Journal:  Clin Transplant       Date:  2001-04       Impact factor: 2.863

7.  Glucose-dependent insulin release from genetically engineered K cells.

Authors:  A T Cheung; B Dayanandan; J T Lewis; G S Korbutt; R V Rajotte; M Bryer-Ash; M O Boylan; M M Wolfe; T J Kieffer
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

8.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

9.  Neogenesis of pancreatic endocrine cells in copper-deprived rat models.

Authors:  I H Al-Abdullah; T Ayala; D Panigrahi; A M Kumar; M S Kumar
Journal:  Pancreas       Date:  2000-07       Impact factor: 3.327

10.  A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.

Authors:  U J Hesse; R Troisi; B Jacobs; B Van Vlem; B de Hemptinne; R Van Holder; F Vermassen; J De Roose; N Lameire
Journal:  Clin Transplant       Date:  2000-08       Impact factor: 2.863

View more
  1 in total

1.  Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model.

Authors:  Ofir Fursht; Mirit Liran; Yuval Nash; Vijay Krishna Medala; Dor Ini; Tabitha Grace Royal; Guy Goldsmith; Limor Nahary; Itai Benhar; Dan Frenkel
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.